Legend Biotech (LEGN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Legend Biotech has reported preliminary net trade sales of approximately $286 million for its CARVYKTI® product in the third quarter of 2024. This announcement reflects data provided by its partner, Janssen Biotech, though it has not been independently verified by Legend Biotech. Investors may find these figures promising as they highlight the company’s growing presence in the biotech market.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
